Bioventix logo

BVXP - Bioventix News Story

4038p -27.0  -0.7%

Last Trade - 2:15pm

Sector
Healthcare
Size
Small Cap
Market Cap £211.8m
Enterprise Value £205.9m
Revenue £10.2m
Position in Universe 822nd / 1820

Bioventix Plc: Director/PDMR Shareholding

Thu 2nd April, 2020 2:21pm
Bioventix plc
(“Bioventix” or the “Company”)

Director/PDMR Shareholding

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that it has been notified that Peter Harrison,
Chief Executive, has dealt in the Ordinary Shares of 5 pence each (the
“Ordinary Shares”) as follows:
* On 1 April 2020, the sale of 30,000 Ordinary Shares at 3,600 pence per
Ordinary Share (the “Sale”); and
* On 2 April 2020, the exercise of options over 18,500 Ordinary Shares at
1,350 pence per Ordinary Share (the “Option Shares”), pursuant to the
Company’s 2013 EMI Share Option Scheme (the “Exercise”) (details of
which can be found at www.bioventix.com).
Following the Sale and the Exercise, Peter Harrison’s total beneficial
interest in the Company will be 416,676 Ordinary Shares representing
approximately 8.0% of the Company.

Following the Exercise, the Company has applied for 18,500 Ordinary Shares to
be admitted to trading on AIM (“Admission”). It is expected that Admission
will occur and that dealings will commence in the Option Shares on 8 April
2020. The Option Shares will rank pari passu with the existing Ordinary
Shares.

The total number of Ordinary Shares in issue following Admission will be
5,207,835 and the Company holds no shares in treasury. Therefore, the total
number of Ordinary Shares with voting rights in the Company will be 5,207,835.

The above figure of 5,207,835 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, Bioventix under
the FCA’s Disclosure Guidance and Transparency Rules.

For further information please contact:

 Bioventix plc Peter Harrison                   Chief Executive Officer  Tel: 01252 728 001  
                                                                                             
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance ECM    Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

 1         Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated (“PCA”)                                                                                            
 a)        Name                                                                                               Peter Harrison                                                                                     
 2.        Reason for the Notification                                                                                                                                                                           
 a)        Position/status                                                                                    Chief Executive Officer                                                                            
 b)        Initial notification/Amendment                                                                     Initial notification                                                                               
 3.        Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                         
 a)        Name                                                                                               Bioventix plc                                                                                      
 b)        LEI                                                                                                213800225MHX7LZQY108                                                                               
 4.        Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted     
 a)        Description of the Financial instrument, type of instrument                                        Ordinary Shares of 5 pence each                                                                    
           Identification code                                                                                GB00B4QVDF07                                                                                       
 b)        Nature of the transaction                                                                          Sale of Ordinary Shares                                                                            
 c)        Price(s) and volume(s)                                                                                                                                                                                
 Price(s)  Volume(s)                                                                                          
 3,600p    30,000                                                                                             
 d)        Aggregated information: · Aggregated volume  · Price                                               30,000  3,600p                                                                                     
 e)        Date of the transaction                                                                            1 April 2020                                                                                       
 f)        Place of the transaction                                                                           London Stock Exchange, AIM Market (XLON)                                                           

   

 1         Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated (“PCA”)                                                                                            
 a)        Name                                                                                               Peter Harrison                                                                                     
 2.        Reason for the Notification                                                                                                                                                                           
 a)        Position/status                                                                                    Chief Executive Officer                                                                            
 b)        Initial notification/Amendment                                                                     Initial notification                                                                               
 3.        Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                         
 a)        Name                                                                                               Bioventix plc                                                                                      
 b)        LEI                                                                                                213800225MHX7LZQY108                                                                               
 4.        Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted     
 a)        Description of the Financial instrument, type of instrument                                        Options over Ordinary Shares of 5 pence each                                                       
           Identification code                                                                                GB00B4QVDF07                                                                                       
 b)        Nature of the transaction                                                                          Exercise of Options                                                                                
 c)        Price(s) and volume(s)                                                                                                                                                                                
 Price(s)  Volume(s)                                                                                          
 1,350p    18,500                                                                                             
 d)        Aggregated information: · Aggregated volume  · Price                                               18,500  1,350p                                                                                     
 e)        Date of the transaction                                                                            2 April 2020                                                                                       
 f)        Place of the transaction                                                                           London Stock Exchange, AIM Market (XLON)                                                           



Copyright (c) 2020 PR Newswire Association,LLC. All Rights Reserved
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.